Vinker Shlomo, Bitterman Haim, Comaneshter Doron, Cohen Arnon D
Chief Physician Office, Central Headquarter, Clalit Health Services, Tel Aviv, Israel ; Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Chief Physician Office, Central Headquarter, Clalit Health Services, Tel Aviv, Israel.
Isr J Health Policy Res. 2015 Jun 1;4:20. doi: 10.1186/s13584-015-0016-9. eCollection 2015.
In 01/2011 Clalit Health Services (CHS), changed the LDL-Cholesterol target definitions in its quality indicators program, from a universal target to values stratified by risk assessment based on ATP III criteria. The objective of this study is to evaluate the effect of this change on achievement of LDL-C targets and on physicians' prescriptions of statins.
A descriptive study based on administrative dataset 06/2010-06/2012.
CHS, The largest health maintenance organization in Israel that insures above 4,000,000 beneficiaries.
PATIENTS who had been in the same risk group throughout the study period.
Attainment of targets for LDL-C and purchases of statins prior to, and following, implementation of the guidelines in the CHS quality indicators program.
433,662 patients remained in the same risk groups throughout the study period; 55.8% were women; the average age was 53.0 ± 10.3 years; 63.9%, 13.4%, and 22.7% were at low, medium, and high risk respectively. After implementation, the proportion of patients reaching LDL-C targets increased in all risk groups: from 58.6% to 61.6%, from 55.1% to 61.1%, and from 44.5% to 49.0%, in low, medium, and high risk groups respectively (p < 0.001). The proportion of patients treated with potent statins increased in all risk groups; from 3.4% to 5.6%, from 6.7% to 10.3%, and from 14.5% to 20.3% respectively (p < 0.001).
The risk stratification approach as a basis for the quality indicators program was implemented and better achievement of target LDL-C levels ensued. We suggest that implementation of quality indicators that are consistent with the current literature can lead to improvements that exceeds temporal trends.
2011年1月,克拉利特医疗服务机构(CHS)在其质量指标项目中更改了低密度脂蛋白胆固醇(LDL - Cholesterol)目标定义,从通用目标改为基于ATP III标准通过风险评估分层的值。本研究的目的是评估这一变化对LDL - C目标达成情况以及医生他汀类药物处方的影响。
基于2010年6月至2012年6月行政数据集的描述性研究。
CHS,以色列最大的健康维护组织,为超过400万受益人提供保险。
在整个研究期间处于同一风险组的患者。
CHS质量指标项目中指南实施前后LDL - C目标的达成情况以及他汀类药物的购买情况。
433,662名患者在整个研究期间处于同一风险组;55.8%为女性;平均年龄为53.0±10.3岁;分别有63.9%、13.4%和22.7%处于低、中、高风险。实施后,所有风险组中达到LDL - C目标的患者比例均有所增加:低风险组从58.6%增至61.6%,中风险组从55.1%增至61.1%,高风险组从44.5%增至49.0%(p<0.001)。所有风险组中接受强效他汀类药物治疗的患者比例均有所增加;分别从3.4%增至5.6%,从6.7%增至10.3%,从14.5%增至20.3%(p<0.001)。
以风险分层方法为基础的质量指标项目得以实施,随后LDL - C目标水平的达成情况有所改善。我们建议,实施与当前文献一致的质量指标可带来超越时间趋势的改善。